+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Travel Vaccines - Global Strategic Business Report

  • PDF Icon

    Report

  • 281 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6107038
The global market for Travel Vaccines was estimated at US$13.2 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Travel Vaccines market.

Global Travel Vaccines Market - Key Trends & Drivers Summarized

Why Are Travel Vaccines Becoming a Prerequisite for International Mobility?

Travel vaccines have emerged as vital safeguards in a globalized world, where the ease of international movement also raises the risk of infectious disease transmission. Vaccines for yellow fever, hepatitis A and B, typhoid, rabies, cholera, and Japanese encephalitis are not only recommended but often mandatory for travelers visiting specific countries. These immunizations protect travelers and host populations alike, acting as essential public health tools in global disease containment.

Heightened awareness following the COVID-19 pandemic has significantly increased the uptake of pre-travel medical consultations and vaccination plans. As governments tighten cross-border health checks, travelers are more willing to comply with immunization schedules. Multilateral health bodies and travel medicine clinics are reinforcing guidelines, and digital vaccine certification systems have been deployed to validate traveler readiness, particularly in higher-risk regions of Africa, Asia, and Latin America.

How Are Technological and Formulation Advances Enhancing Vaccine Uptake?

The field of vaccinology is undergoing significant innovation, with mRNA platforms, thermostable formulations, and combination vaccines being tailored for travel use. These advances are reducing cold chain dependency, extending shelf life, and simplifying dosage schedules-key benefits for last-minute or remote-area travelers. Some travel vaccines now require just one dose or offer oral options, improving compliance and accessibility.

Another key development is the integration of electronic health records and mobile apps that automate reminders and provide guidance based on destination-specific risks. Clinics are offering bundled packages with tailored vaccine plans and digital certificates. Additionally, prefilled syringes, microneedle patches, and intranasal formulations are enhancing administration safety and efficiency, particularly for pediatric and elderly populations.

Which Traveler Segments and Destinations Are Fueling Demand?

Tourists, humanitarian workers, international students, and business travelers to high-risk regions are primary consumers of travel vaccines. The surge in eco-tourism, rural tourism, and adventure travel increases exposure to vector-borne diseases and zoonoses, driving vaccination needs. Additionally, corporate travel to emerging markets and global supply chain expansion has led to a rise in enterprise-funded immunization programs.

The demand is also rising in non-traditional traveler categories such as digital nomads, missionaries, and expatriates, who require long-term or multiple booster doses. Destination-specific health risks and outbreak alerts frequently alter vaccine requirements, prompting last-minute surges in demand at travel clinics. Furthermore, national mandates and health advisories continue to influence both vaccine availability and traveler compliance.

The Growth in the Travel Vaccines Market Is Driven by Several Factors

Expansion in global travel volumes, heightened awareness of region-specific disease risks, and stricter cross-border health protocols are key growth enablers. Advancements in vaccine platforms-including mRNA, conjugate, and recombinant technologies-are increasing the availability and efficacy of travel vaccines. The rise in adventure, eco-tourism, and off-grid travel is pushing more travelers into regions with higher pathogen exposure, necessitating preemptive immunization. Digital health tools and mobile vaccine passport systems are streamlining pre-travel compliance, encouraging more consistent uptake. Additionally, institutional support from governments and global health organizations, alongside private sector initiatives in workforce protection, are further accelerating market momentum.

Scope Of Study:

The report analyzes the Travel Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Disease Type (Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines, Typhoid & Other Vaccines); End-Use (Adult End-Use, Pediatric End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Influenza Vaccines segment, which is expected to reach US$9.4 Billion by 2030 with a CAGR of a 5.5%. The Diphtheria Vaccines segment is also set to grow at 4.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.6 Billion in 2024, and China, forecasted to grow at an impressive 9.4% CAGR to reach $3.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Travel Vaccines Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Travel Vaccines Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Travel Vaccines Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, ALK-Abelló A/S, AstraZeneca PLC, Bavarian Nordic A/S, CSL Limited and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Travel Vaccines market report include:

  • Abbott Laboratories
  • ALK-Abelló A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.?Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals (J&J)
  • Merck & Co., Inc.
  • Moderna Inc. (if included)
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Travel Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising International Travel and Cross-Border Movement Drives Demand for Pre-Travel Vaccinations
  • Increased Awareness of Endemic Disease Risks in Emerging Destinations Fuels Preventive Vaccine Uptake
  • Growth in Business, Educational, and Medical Tourism Supports Volume Demand
  • Expanded Inclusion of Yellow Fever, Typhoid, Hepatitis, and Meningococcal Vaccines in Pre-Travel Protocols
  • Regulatory Requirements for Entry Into Certain Countries Drive Compliance-Driven Vaccine Demand
  • Use of Combination and Single-Dose Formulations Improves Convenience and Reduces Missed Doses
  • Growth in Private Clinics and Travel Health Centers Enhances Access to Targeted Immunizations
  • Increased Awareness Campaigns by Health Ministries and Airlines Support Preventive Measures
  • Seasonal Travel Peaks Correlate With Vaccine Appointment Upticks in Urban Markets
  • Availability of Pre-Filled Syringes and Multi-Dose Packs Improves Distribution Efficiency
  • Travel Health App Integrations Support Vaccine Reminders and Record Management
  • Adoption in Backpacking, Volunteer, and High-Risk Travel Segments Sustains Niche Growth
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Travel Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Travel Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Influenza Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Influenza Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Diphtheria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hepatitis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Hepatitis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Typhoid & Other Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Typhoid & Other Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Adult End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Adult End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pediatric End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Pediatric End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
JAPAN
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
CHINA
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: China 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
EUROPE
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Travel Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
FRANCE
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: France 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
GERMANY
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
UNITED KINGDOM
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
ASIA-PACIFIC
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Travel Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Travel Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Travel Vaccines by Disease Type - Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Travel Vaccines by Disease Type - Percentage Breakdown of Value Sales for Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines and Typhoid & Other Vaccines for the Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Travel Vaccines by End-Use - Adult End-Use and Pediatric End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Travel Vaccines by End-Use - Percentage Breakdown of Value Sales for Adult End-Use and Pediatric End-Use for the Years 2014, 2025 & 2030
AUSTRALIA
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Travel Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • ALK-Abelló A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • CSL Limited
  • F.?Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals (J&J)
  • Merck & Co., Inc.
  • Moderna Inc. (if included)
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi S.A.
  • Valneva SE

Table Information